December 16, 2021 11:55 AM EST
Manufacturing

Drug­mak­ers seek tweaks to ICH guid­ance on con­tin­u­ous man­u­fac­tur­ing

Zachary Brennan

Senior Editor

Eli Lil­ly, Gilead, Ther­mo Fish­er and oth­er in­dus­try groups and non­prof­its like BIO and USP are seek­ing some slight changes and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

At AS­CO, cell ther­a­pies for dead­ly form of brain can­cer make ear­ly strides

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Kymera un­veils ‘ex­cep­tion­al’ Phase 1 da­ta for its Dupix­ent-in-a-pill pro­gram

Phase 3 or bust: Why Lil­ly won't run mid-stage can­cer tri­als

DOGE set to­day as their last day at FDA. In­stead, they're con­tin­u­ing to get full pay and don't work

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times